<DOC>
	<DOCNO>NCT01740388</DOCNO>
	<brief_summary>To evaluate clinical microbial efficacy besifloxacin ophthalmic suspension , 0.6 % ( Besifloxacin ) administer BID 3 day compare vehicle treatment bacterial conjunctivitis .</brief_summary>
	<brief_title>Clinical Microbial Efficacy Besifloxacin Ophthalmic Suspension , 0.6 % Treatment Bacterial Conjunctivitis</brief_title>
	<detailed_description />
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Conjunctivitis , Bacterial</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>7- ( 3-aminohexahydro-1H-azepin-1-yl ) -8-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid</mesh_term>
	<criteria>Have clinical diagnosis acute bacterial conjunctivitis exhibit mucopurulent/purulent conjunctival discharge ( crusty sticky eyelid ) redness least 1 eye . A minimum score 1 present discharge bulbar conjunctival injection . Have monocular pinholed Snellen visual acuity ( VA ) equal good 20/200 eye . Age appropriate VA testing perform . Every effort make obtain VA measurement child . If VA unobtainable child , Investigator 's discretion include subject study . Be willing discontinue contact lens wear duration study . Have severe/serious ocular condition history/presence chronic generalize systemic disease Investigator feel might increase risk subject confound result ( ) study . Have know hypersensitivity contraindication besifloxacin , fluoroquinolones , ingredient study drug . Be expect require treatment systemic ocular ( either eye ) nonsteroidal antiinflammatory drug ( NSAIDs ) , antihistamine , corticosteroid study use medication within 2 day prior study start . Be expect require concurrent ocular therapy either eye ophthalmic solution ( unless specify ) , include tear substitute , study use ophthalmic solution within 2 hour prior study start . Be expect require concurrent ocular therapy ( either eye ) mast cell stabilizer decongestant study use within 2 day prior study start . Be expect require concurrent systemic ocular therapy immunosuppressant ( eg , Restasis ) study use systemic ocular immunosuppressant within 30 day prior study start . Be expect require treatment systemic ocular ( either eye ) antibacterial ( study drug ) study use systemic ocular antibacterial within 3 day prior study start . Be likely require antimicrobial therapy condition respiratory tract infection , urinary tract infection , skin/soft tissue infection , otitis medium study . Have ocular surgery ( include laser surgery ) either eye within 6 week prior entry study . Have suspect viral allergic conjunctivitis disease condition could interfere efficacy safety evaluation study medication . Have suspect iritis Have history recurrent corneal erosion syndrome , either idiopathic secondary previous corneal trauma dry eye syndrome . Have active ulcerative keratitis , specifically epithelial loss great punctate keratitis . Be immune compromise .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>